ATE243522T1 - Verwendung von tall-104 zellen in kombination mit adriamyzin oder cisplatin zur behandlung von malignen tumoren - Google Patents

Verwendung von tall-104 zellen in kombination mit adriamyzin oder cisplatin zur behandlung von malignen tumoren

Info

Publication number
ATE243522T1
ATE243522T1 AT98920098T AT98920098T ATE243522T1 AT E243522 T1 ATE243522 T1 AT E243522T1 AT 98920098 T AT98920098 T AT 98920098T AT 98920098 T AT98920098 T AT 98920098T AT E243522 T1 ATE243522 T1 AT E243522T1
Authority
AT
Austria
Prior art keywords
adriamycin
cisplatin
tall
combination
cells
Prior art date
Application number
AT98920098T
Other languages
English (en)
Inventor
Daniela Santoli
Giovanni Rovera
Alessandra Cesano
Original Assignee
Wistar Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wistar Inst filed Critical Wistar Inst
Application granted granted Critical
Publication of ATE243522T1 publication Critical patent/ATE243522T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C12N5/0694—Cells of blood, e.g. leukemia cells, myeloma cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/51—Stomach
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT98920098T 1997-05-01 1998-04-30 Verwendung von tall-104 zellen in kombination mit adriamyzin oder cisplatin zur behandlung von malignen tumoren ATE243522T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/847,000 US6022538A (en) 1995-06-06 1997-05-01 Method of treating malignancies
PCT/US1998/008835 WO1998048630A1 (en) 1997-05-01 1998-04-30 Method of treating malignancies

Publications (1)

Publication Number Publication Date
ATE243522T1 true ATE243522T1 (de) 2003-07-15

Family

ID=25299529

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98920098T ATE243522T1 (de) 1997-05-01 1998-04-30 Verwendung von tall-104 zellen in kombination mit adriamyzin oder cisplatin zur behandlung von malignen tumoren

Country Status (11)

Country Link
US (1) US6022538A (de)
EP (1) EP0980205B1 (de)
JP (1) JP4371437B2 (de)
AT (1) ATE243522T1 (de)
AU (1) AU734046B2 (de)
CA (1) CA2288059C (de)
DE (1) DE69815840T2 (de)
DK (1) DK0980205T3 (de)
ES (1) ES2202847T3 (de)
PT (1) PT980205E (de)
WO (1) WO1998048630A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001522226A (ja) 1997-01-31 2001-11-13 リサーチ コーポレイション テクノロジーズ インコーポレイテッド セミ−同種異系細胞での癌の免疫療法
AU7267398A (en) * 1997-04-30 1998-11-24 Hans Klingemann Natural killer cell lines and methods of use
US8034332B2 (en) 1997-04-30 2011-10-11 Conkwest, Inc. Interleukin-secreting natural killer cell lines and methods of use
US6157376A (en) * 1998-09-30 2000-12-05 Genesis Microchip, Corp. Method and apparatus for generating a target clock signal having a frequency of X/Y times the frequency of a reference clock signal
US6828147B1 (en) 1999-02-24 2004-12-07 The Wistar Institute Of Anatomy And Biology Method of modifying cytotoxic cells and uses thereof
DE10112851C1 (de) 2001-03-16 2002-10-10 Gsf Forschungszentrum Umwelt Semi-allogene Antitumor-Vakzine mit HLA-haplo-identischen Antigen-präsentierenden Zellen
DE10132502A1 (de) 2001-07-05 2003-01-23 Gsf Forschungszentrum Umwelt Angriff auf Tumorzellen mit fehlender, niedriger oder anormaler MHC-Expression durch kombinieren von nicht MHC-Restringierten T-Zellen/NK-Zellen und MHC-Restringierten Zellen
US20040115173A1 (en) * 2002-02-15 2004-06-17 Daniela Santoli Method of treating inflammation, particularly diabetes
CA2589034C (en) * 2004-11-02 2016-05-31 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Compositions and methods for treating hyperproliferative disorders
CA2603191A1 (en) * 2005-03-29 2006-10-05 The Board Of Trustees Of The University Of Illinois Cancer vaccines and therapeutic methods
CN110179976A (zh) * 2019-05-22 2019-08-30 华中科技大学同济医学院附属同济医院 用于治疗癌症的组合药物制剂

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166059A (en) * 1987-06-16 1992-11-24 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy using gene fusions for genetic or acquired disorders
US5126132A (en) * 1989-08-21 1992-06-30 The United States Of America As Represented By The Department Of Health And Human Services Tumor infiltrating lymphocytes as a treatment modality for human cancer
US5272082A (en) * 1992-03-30 1993-12-21 The Wistar Institute Of Anatomy & Biology Cytotoxic T-ALL cell lines and uses therefor
DK0697875T3 (da) * 1993-05-14 2002-04-29 Wistar Inst Anvendelse af modificerede TALL-104 celler til behandling af cancer og virale sygdomme

Also Published As

Publication number Publication date
PT980205E (pt) 2003-11-28
JP4371437B2 (ja) 2009-11-25
CA2288059A1 (en) 1998-11-05
WO1998048630A1 (en) 1998-11-05
DK0980205T3 (da) 2003-10-20
DE69815840T2 (de) 2004-05-06
CA2288059C (en) 2010-07-06
JP2002512618A (ja) 2002-04-23
US6022538A (en) 2000-02-08
AU734046B2 (en) 2001-05-31
EP0980205A4 (de) 2001-11-07
ES2202847T3 (es) 2004-04-01
AU7274498A (en) 1998-11-24
EP0980205A1 (de) 2000-02-23
DE69815840D1 (de) 2003-07-31
EP0980205B1 (de) 2003-06-25

Similar Documents

Publication Publication Date Title
BRPI0409919A (pt) combinações para o tratamento de doenças envolvendo proliferação, migração ou apoptose celular de células de células de mieloma, ou angiogênese
IL162836A0 (en) Peptides and peptidommetics having anti-proliferative activity and/or that augment nucleic acid damaging agents or treatments
IL134445A0 (en) A method of preventing or treating estrogen-dependent diseases and disorders
DE69533036D1 (de) Adenovirus e1a polypeptid kodierende nukleinsäure zur sensibilisierung von tumorzellen für chemotherapie oder radiotherapie
ATE243522T1 (de) Verwendung von tall-104 zellen in kombination mit adriamyzin oder cisplatin zur behandlung von malignen tumoren
UA86586C2 (ru) Комбинация для лечения заболеваний, связанных с клеточной пролиферацией, миграцией или апоптозом клеток миеломы или с ангиогенезом
NO994330D0 (no) Metode for behandling av en tumor
ATE406897T1 (de) Kombination von et-743 mit 5-fluorouracil pro- drugs zur behandlung von krebs
DE69902523D1 (de) Verwendung von erythropoietin zur behandlung von multiple myelom
IL141550A0 (en) Methods and compositions for the prevention or treatment of cancer
ATE271873T1 (de) Verwendung von glukosamin und glukosaminderivaten zur schnellen linderung von juckreiz oder lokalisiertem schmerz
DE69533873D1 (de) Krebstherapie mit lymphotoxin
PT971710E (pt) Utilizacao de queleritrina e radiacao para terapia de tumores
DE69232596D1 (de) Inhibitor von nebenwirkungen zur krebstherapy
ATE206052T1 (de) Verwendung von sphingosin-1-phosphat, sphingosin- 1-phosphat-derivaten und/oder deren gemische zur behandlung von entzündlichen hautkrankheiten
EP2210956A3 (de) Verfahren zur Hemmung von Zellwachstum mit Oligonukleotiden
MD1569G2 (ro) Metodă de tratament al cancerului mamar în perioada preoperatorie
EP1827471A4 (de) Zusammensetzung und verfahren zur erhöhung der apoptose in krebszellen
ES2062517T3 (es) Quimioterapia local con 4-hidroperoxiciclofosfamida.
DE60020352D1 (de) Zusammensetzung und methode zur induzierung von apoptosis in prostatakrebszellen mittels m-dna und mcc
ZA99723B (en) Recombinant proteins derived from HGF and MSP.
WO2004098504A3 (en) Antitumor 2-aminocarbonyl-1,2-bis(methylsulfonyl)-1-(2-chloroethyl)hydrazines and methods of treating tumors
DE59809592D1 (de) Verwendung von putamen ovi

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0980205

Country of ref document: EP